Fig. 1. Profile of vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on platform and clinical stage. 63 vaccine candidates are in clinical evaluation, while 179 candidates are still in the preclinical stage. The highest frequency is related to protein subunit vaccines and none of the vaccines with LABV and rBV platforms have entered the clinical experiments. nrVV, non-replicating viral vector; rVV, replicating viral vector; VLP, virus-like particles; rBV, replicating bacteria vector; LABV, live attenuated bacterial vector.
Table 2. The pioneers in the race of putative vaccine candidates against COVID-19 according to the World Health Organization reports.